Vaidya Ashok Db
Kasturba Health Society- Medical Research Centre, Mumbai, India.
J Ayurveda Integr Med. 2024 Jan-Feb;15(1):100856. doi: 10.1016/j.jaim.2023.100856. Epub 2024 Jan 3.
There is already a significant global initiative to explore the synergy between traditional medicine (TM) and oncology, for holistic best care of cancer patients. Integrative oncology clinics have emerged with operational efficiency. What is needed now is an integrative vision that inspires to seamlessly coordinate the trans-system efforts in cancer research and rapidly translate the positive outcomes into prevention and treatment of cancer. The current dominant paradigm to consider TM only for complementary and alternative adjunct usage cannot inspire state-of-the art research and development on TM leads and serendipitous discoveries. Ayurvedic concepts of Vyadhi-kshamatwa (Immune resistance), Shatkriyakala (Six stages of a disease) and Hetuviparya Chikitsa (Reversal of pathogenetic factors) need to be synergized with ayurvedic pharmacoepidemiology, reverse pharmacology, observational therapeutics, ayurgenomics, ayurvedic biology, and reverse ayurceutics. Such a paradigm-shifting vision may lead to pragmatic translational research/practice and system obstacles and novel bridges in Integrative Oncology.
目前已有一项重要的全球倡议,旨在探索传统医学(TM)与肿瘤学之间的协同作用,以实现癌症患者的全面最佳护理。综合肿瘤诊所已高效运作起来。现在需要的是一种综合愿景,以激励无缝协调癌症研究中的跨系统努力,并迅速将积极成果转化为癌症的预防和治疗。当前仅将传统医学视为补充和替代辅助用途的主导范式,无法激发对传统医学线索的前沿研发和意外发现。阿育吠陀的Vyadhi-kshamatwa(免疫抵抗)、Shatkriyakala(疾病的六个阶段)和Hetuviparya Chikitsa(致病因素的逆转)概念需要与阿育吠陀药物流行病学、逆向药理学、观察性治疗学、阿育吠陀基因组学、阿育吠陀生物学和逆向阿育吠陀治疗学协同作用。这种范式转变的愿景可能会带来务实的转化研究/实践以及综合肿瘤学中的系统障碍和新型桥梁。